Fred Alger Management LLC Purchases Shares of 3,728 Krystal Biotech, Inc. $KRYS

Key Points

• Fred Alger Management LLC acquired 3,728 shares of Krystal Biotech, Inc. (NASDAQ:KRYS) valued at approximately $672,000 in the first quarter.
• Shares of Krystal Biotech have seen a 2.7% decline, currently trading around $137.46, with a market cap of $3.98 billion.
• Analysts generally rate Krystal Biotech as a "Moderate Buy", with an average target price of $209.00, amidst several recent upgrades and downgrades from financial institutions.

Fred Alger Management LLC acquired a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 3,728 shares of the company's stock, valued at approximately $672,000.

Other institutional investors have also recently made changes to their positions in the company. Nuveen LLC purchased a new position in shares of Krystal Biotech during the 1st quarter worth about $42,223,000. Braidwell LP boosted its position in shares of Krystal Biotech by 99.9% during the first quarter. Braidwell LP now owns 400,744 shares of the company's stock valued at $72,254,000 after buying an additional 200,244 shares during the period. T. Rowe Price Investment Management Inc. bought a new position in shares of Krystal Biotech during the first quarter valued at approximately $33,455,000. Soleus Capital Management L.P. raised its holdings in shares of Krystal Biotech by 65.2% in the fourth quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock worth $56,144,000 after buying an additional 141,400 shares during the period. Finally, 1832 Asset Management L.P. purchased a new stake in shares of Krystal Biotech in the first quarter worth approximately $24,521,000. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Trading Down 0.5%

Shares of Krystal Biotech stock traded down $0.68 during trading on Friday, hitting $143.68. 350,777 shares of the stock traded hands, compared to its average volume of 250,236. The stock's fifty day simple moving average is $146.81 and its 200 day simple moving average is $152.58. The firm has a market cap of $4.16 billion, a P/E ratio of 29.20 and a beta of 0.66. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. The company had revenue of $96.04 million during the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. As a group, equities analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on KRYS. Chardan Capital dropped their price objective on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a report on Friday, August 22nd. Bank of America lowered their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Citigroup restated a "neutral" rating and issued a $166.00 price target (down from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Finally, HC Wainwright reiterated a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a report on Friday, August 22nd. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Krystal Biotech has a consensus rating of "Moderate Buy" and an average price target of $209.00.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 1,389 shares of the stock in a transaction that occurred on Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total transaction of $208,350.00. Following the transaction, the insider directly owned 1,508,056 shares in the company, valued at approximately $226,208,400. This trade represents a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders have sold 49,800 shares of company stock valued at $7,487,943. 13.70% of the stock is currently owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).